TissueGen is developing solutions to reduce ophthalmic inflammation and pain following surgery, lower the high treatment burden resulting from repeated injections of costly medications, provide neuroprotection through mitigation of secondary neurodegeneration processes, and improve the healing process following damage to peripheral nerves.
INFLAMMATION AND PAIN
Frequent drop administration post-surgery - The treatment of post-surgical ocular pain and inflammation is routinely done via daily administration of topical drops, an age-old staple of ophthalmic care that poses multiple challenges:
HIGH TREATMENT BURDEN
Repeated Intravitreal injections of anti-VEGF medications have been the treatment of choice for a variety of exudative retinal diseases since the early 2000s. Repeated monthly injections pose several challenges:
In cases of peripheral nerve transection, regeneration is slow and often incomplete. Less than half of patients who undergo nerve repair after injury regain satisfactory motor or sensory function. This is further reduced with large nerve gaps of 3 cm and more.
SECONDARY NEURONAL DEGENERATION
There is currently no neuroprotective treatment in chronic neurodegenerative diseases of the eye. Our goal is to mitigate secondary degeneration processes in the optic nerve and the retinal ganglion cell layer.